WO2023245245A1 - Détection de lésions cellulaires - Google Patents

Détection de lésions cellulaires Download PDF

Info

Publication number
WO2023245245A1
WO2023245245A1 PCT/AU2023/050562 AU2023050562W WO2023245245A1 WO 2023245245 A1 WO2023245245 A1 WO 2023245245A1 AU 2023050562 W AU2023050562 W AU 2023050562W WO 2023245245 A1 WO2023245245 A1 WO 2023245245A1
Authority
WO
WIPO (PCT)
Prior art keywords
kidney
seq
cfdna
damage
ddc
Prior art date
Application number
PCT/AU2023/050562
Other languages
English (en)
Inventor
David Hugh MURRAY
Nicola Rosalind BOULTER
Original Assignee
Garvan Institute Of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2022901697A external-priority patent/AU2022901697A0/en
Application filed by Garvan Institute Of Medical Research filed Critical Garvan Institute Of Medical Research
Publication of WO2023245245A1 publication Critical patent/WO2023245245A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Definitions

  • the present disclosure relates to methods and compositions for detecting cell, tissue and organ damage using cell free DNA.
  • cfDNA Cell free DNA
  • cfDNA Cell free DNA
  • dd-cfDNA donor-derived cell free DNA
  • Organ-specific cfDNA detection has been achieved using Y-chromosomal markers in female patients receiving an organ from a male donor. More recently, massively parallel sequencing methods have been used to identify donor-specific alleles or single-nucleotide polymorphisms (SNPs). However, dd-cfDNA assays are only applicable to situations where chimerism exists, such as in organ transplant recipients.
  • Epigenetic modifications play an important role in regulating cell-specific expression patterns.
  • Different DNA methylation signatures for example, can be found in different tissues and even between different cell types within a particular tissue.
  • the inventors found that these epigenetic signatures can be used to identify cfDNA tissue of origin.
  • these novel epigenetic markers can be used to detect cell, tissue or organ damage, including autologous cell, tissue or organ damage.
  • the present disclosure provides a method of diagnosing organ damage in a subject the method comprising detecting an organ-specific epigenetic marker in cfDNA obtained from a biological sample of the subject, wherein the presence of the epigenetic marker in the cfDNA is indicative of organ damage.
  • the present disclosure provides a method of detecting organ damage in a subject, the method comprising: a) obtaining a biological sample comprising cfDNA from the subject; and b) detecting an organ-specific epigenetic marker in the cfDNA of the sample, wherein the presence of the epigenetic marker in the cfDNA of the sample is indicative of organ damage.
  • present disclosure provides a method of identifying at least one methylated region in cfDNA, said method comprising the steps of:
  • the method comprises monitoring kidney damage during renal replacement therapy.
  • the method comprises detecting an increase in the level of the epigenetic marker relative to a reference level. In some examples, the method comprises detecting an increase in the level of the epigenetic marker over time.
  • the epigenetic marker is preferably DNA methylation status at a differentially methylated region of the cfDNA.
  • the method comprises detecting cfDNA methylation status at more than one differentially methylated region.
  • the methylation status may be determined at more than one differentially methylated region using a multiplex assay.
  • the methylation status is determined by a method that does not involve genomic DNA sequencing.
  • the methylation status is preferably determined by a method that does not involve DNA sequencing.
  • the methylation status may, for example, be determined by treating the cfDNA with bisulfite and amplifying the differentially methylated region using polymerase chain reaction (PCR).
  • the PCR may be digital PCR (dPCR), droplet digital PCR (ddPCR) or quantitative PCR (qPCR).
  • the organ is a kidney.
  • the organ damage may be associated with acute kidney injury (AKI), chronic kidney disease (CKD) or kidney transplant rejection following organ donation.
  • the organ damage is associated with chemotherapy or radiotherapy.
  • the biological sample may be saliva, blood or serum or plasma, urine, semen, vitreous fluid, lymph fluid, synovial fluid, follicular fluid, gastric fluid, intestinal fluid, bile, tumour fluid, interstitial fluid, amniotic fluid, mucus, breast milk, pleural fluid, sweat, tears, stool, serum or cerebro-spinal fluid.
  • the present disclosure provides a method of diagnosing kidney damage in a subject, the method comprising detecting at least one kidney differentially methylated region in cfDNA wherein the cfDNA is obtained from a biological sample of the subject, and wherein the presence of the at least one kidney differentially methylated region in the cfDNA is indicative of kidney damage.
  • the present disclosure provides a method of detecting kidney damage in a subject, the method comprising: a) obtaining a biological sample comprising cfDNA from the subject; and b) detecting at least one kidney differentially methylated region in the cfDNA, wherein the presence of the at least one kidney-specific methylation site in the cfDNA is indicative of organ damage.
  • method comprises detecting an increase in the level of the at least one kidney differentially methylated region relative to a reference level. In further examples, the method comprises detecting an increase in the level of the at least one kidney differentially methylated region over time. In still further examples, the method comprises detecting cfDNA methylation status at more than one kidney differentially methylated region. In yet further examples of the method, the methylation status is determined at more than one kidney differentially methylated region using a multiplex assay. In certain examples of the method, the methylation status is determined by a method that does not involve DNA sequencing.
  • the methylation status is determined by treating the cfDNA with bisulfite and amplifying the at least one kidney differentially methylated region using polymerase chain reaction (PCR), where the PCR is, for example, digital PCR (dPCR), digital droplet PCR (ddPCR) or quantitative PCR (qPCR).
  • PCR polymerase chain reaction
  • dPCR digital PCR
  • ddPCR digital droplet PCR
  • qPCR quantitative PCR
  • the subject and the kidney are autologous.
  • the kidney damage is associated with acute kidney injury, chronic kidney disease or kidney transplant rejection or Renal replacement therapy.
  • the kidney damage is associated with chemotherapy or radiotherapy.
  • the biological sample is urine.
  • the method specifically detects damage to a defined tissue or cell-type of the kidney. For example, damage to renal proximal tubule epithelial cells, or damage to podocytes.
  • the subject is a human.
  • the subject is non-human.
  • the non-human subject is, for example, a domesticated animal or a companion animal, where a domesticated animal can for example, be selected from the group consisting of sheep, cattle, horses, cats, dogs, pigs, and chickens and a companion animal can be selected from, for example, cats and dogs.
  • the method further comprises treating the subject for the kidney damage.
  • the differentially methylated region is located at one or more loci selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L, PAX2, chr12 - 122277360 (CLIP 1), chr17 - 35303285, DEF6, EMX1 , HPD, PDE4D and SPAG5.
  • the differentially methylated region is located at one or more loci selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L and PAX2.
  • the differentially methylated regions are located at two loci selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L and PAX2.
  • the differentially methylated regions may be located at: GRAMD1 B and DDC; GRAMD1 B and MAST4; GRAMD1 B and MCF2L; GRAMD1 B and PAX2; DDC and MAST4; DDC and MCF2L; DDC and PAX2; MAST4 and MCF2L; MAST4 and PAX2; or MCF2L and PAX2.
  • the differentially methylated regions are located at three loci selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L and PAX2.
  • the differentially methylated regions may be located at: GRAMD1 B, DDC and MAST4; GRAMD1 B, DDC and MCF2L; GRAMD1 B, DDC and PAX2; GRAMD1 B, MAST4 and MCF2L; GRAMD1 B, MAST4 and PAX2; GRAMD1 B, MCF2L and PAX2; DDC, MAST4 and MCF2L; DDC, MAST4 and PAX2; DDC, MCF2L and PAX2; or MAST4; MCF2L and PAX2.
  • the differentially methylated regions are located at four loci selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L and PAX2.
  • the differentially methylated regions may be located at GRAMD1 B, DDC, MAST4 and MCF2L; GRAMD1 B, DDC, MAST4 and PAX2; GRAMD1 B, MAST4, MCF2L and PAX2; GRAMD1 B, DDC, MCF2L and PAX2; or DDC, MAST4, MCF2L and PAX2.
  • the differentially methylated regions are located at GRAMD1 B, DDC, MAST4, MCF2L and PAX2.
  • the differentially methylated region may comprise a sequence having at least 90% identity to any one or more of SEQ ID NO. 1 , SEQ ID NO. 2 SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 22, SEQ ID NO. 23, SEQ ID NO. 29 or SEQ ID NO. 30.
  • tissue damage may include damage to a specific cell- or tissue-type within the tissue.
  • the method specifically detects damage to a defined tissue or celltype of the organ.
  • the defined cell-type may be renal proximal tubule epithelial cells.
  • the differentially methylated regions may be located at at least one of GRAMD1 B, DDC, MAST4, MCF2L, PAX2, chr12 - 122277360 (CLIP 1) chr17 - 35303285, DEF6, EMX1 , HPD, PDE4D and SPAG5.
  • the method further comprises treating the subject for the organ damage.
  • the present disclosure also provides a method of treating organ damage in a subject, the method comprising: i) detecting an organ-specific epigenetic marker in cfDNA obtained from a biological sample of the subject, wherein the presence of the epigenetic marker in the cfDNA is indicative of organ damage; and ii) treating the subject for the organ damage.
  • the present disclosure provides a method of indicating to a user whether or not a subject has organ damage, the method comprising: a) producing sample epigenetic data by determining a level of an organ-specific epigenetic marker in cell-free DNA obtained from a biological sample of the subject; b) a processor receiving the sample epigenetic data, wherein the processor also receives reference epigenetic data corresponding to the epigenetic marker; c) the processor generating differential epigenetic data by comparing the sample epigenetic data with the reference epigenetic data; d) the processor processing the differential epigenetic data to produce a damage index value; e) determining by the processor a damage status of the subject based upon the damage index value, the damage status being indicative of whether or not the subject has organ damage; and f) transferring an indication of the disease status of the subject to the user via a communications network.
  • the method of the invention relates to a companion diagnostic that is used in conjunction with other diagnostic markers and/or reference data or a subject’s details to determine or predict kidney damage in the subject.
  • Other diagnostic markers can include but are not limited to elevated blood and/or urine creatinine levels, elevated blood urea nitrogen (BUN), glomerular filtration levels, urine albumimcreatinine ratio and hyperlipidemia.
  • Reference data or a subject’s details can include but are not limited to the subject’s age, weight, alcohol intake, smoking status, intake of drugs or medication regime, physical fitness or lack thereof, blood pressure, existing or susceptibility to a disease, stress or mental illness, cardiovascular disease and stroke.
  • the epigenetic marker is preferably DNA methylation status at a differentially methylated region within the cfDNA.
  • the differentially methylated region is located at one or more loci selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L, PAX2, chr12 - 122277360 (CLIP1), chr17 - 35303285, DEF6, EMX1 , HPD, PDE4D and SPAG5.
  • the differentially methylated region is located at one or more loci selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L and PAX2.
  • the differentially methylated regions are located at two loci selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L and PAX2.
  • the differentially methylated regions may be located at: GRAMD1 B and DDC; GRAMD1 B and MAST4; GRAMD1 B and MCF2L; GRAMD1 B and PAX2; DDC and MAST4; DDC and MCF2L; DDC and PAX2; MAST4 and MCF2L; MAST4 and PAX2; or MCF2L and PAX2.
  • the differentially methylated regions are located at three loci selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L and PAX2.
  • the differentially methylated regions may be located at: GRAMD1 B, DDC and MAST4; GRAMD1 B, DDC and MCF2L; GRAMD1B, DDC and PAX2; GRAMD1 B, MAST4 and MCF2L; GRAMD1 B, MAST4 and PAX2; GRAMD1 B, MCF2L and PAX2; DDC, MAST4 and MCF2L; DDC, MAST4 and PAX2; DDC, MCF2L and PAX2; or MAST4; MCF2L and PAX2.
  • the differentially methylated regions are located at four loci selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L and PAX2.
  • the differentially methylated regions may be located at GRAMD1 B, DDC, MAST4 and MCF2L; GRAMD1 B, DDC, MAST4 and PAX2; GRAMD1 B, MAST4, MCF2L and PAX2; GRAMD1 B, DDC, MCF2L and PAX2; or DDC, MAST4, MCF2L and PAX2.
  • the differentially methylated regions are located at GRAMD1 B, DDC, MAST4, MCF2L and PAX2.
  • the differentially methylated region may comprise a sequence having at least 90% identity to any one or more of SEQ ID NO. 1 , SEQ ID NO. 2 SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 22, SEQ ID NO. 23, SEQ ID NO. 29 or SEQ ID NO. 30.
  • the present invention relates to methods that use differential methylation specifically in kidney cells.
  • one of the key advantages relates to the ability to selectively amplify methylated targets sequences and exclude non-methylated versions of the genes.
  • amplifying and identifying only kidney cfDNA This approach not only allows for PCR-based assays but also offers an alternative low-cost sequencing-based embodiment.
  • the potential of incorporating sequencing into one embodiment of the method of the invention provides a beneficial alternative pathway to overcome limitations associated with PCR alone. Nevertheless, a PCR assay of the present invention remains commercially viable due to its widespread use and relatively low expenditure required for setup.
  • the present invention is not limited to any particular differentially methylated region within the described loci.
  • the present invention can be carried out using at least one of a number of differentially methylated regions that occur within the described loci.
  • sample epigenetic data and the reference epigenetic data is based upon more than one epigenetic marker.
  • the processor processes the differential epigenetic data using a univariate and/or multivariate analysis.
  • the subject may be a human or non-human subject, where a non-human subject is for example, a domesticated animal or a companion animal, where a domesticated animal can for example, be selected from the group consisting of sheep, cattle, horses, cats, dogs, pigs, and chickens and a companion animal can be selected from, for example, cats and dogs.
  • a non-human subject is for example, a domesticated animal or a companion animal
  • a domesticated animal can for example, be selected from the group consisting of sheep, cattle, horses, cats, dogs, pigs, and chickens
  • a companion animal can be selected from, for example, cats and dogs.
  • the subject is a human.
  • the present disclosure provides at least one nucleotide primer or nucleotide probe sequence when used in the method of the invention to detect at least one kidney differentially methylated region of cfDNA.
  • the at least one nucleotide primer or probe is two nucleotide primers when used in a PCR to detect a kidney differentially methylated region in cfDNA.
  • the present disclosure provides a kit for use in diagnosing kidney damage in a subject comprising at least one reagent for detecting at least one kidney differentially methylated region in cfDNA wherein the cfDNA is from a biological sample of the subject including instructions for use in the method of the invention.
  • the at least one reagent for detecting at least one kidney differentially methylated region in cfDNA is at least one nucleotide primer or nucleotide probe, and in certain examples, two nucleotide primers configured to detect at least one kidney differentially methylated region in cfDNA.
  • the present disclosure provides a use of at least one kidney differentially methylated region in cfDNA in the manufacture of a reagent for diagnosing kidney damage in a subject.
  • the reagent is at least one nucleotide primer or nucleotide probe, and in certain examples, two nucleotide primers configured to detect at least one kidney differentially methylated region in cfDNA.
  • FIG. 1 Candidate regions of interest plotted with the Hg19 location of each CpG probe on the x-axis and the Beta value (proportion methylated) on the y-axis. Regions of interest include DDC (A), MAST4 (B), PAX2 (C), MCF2L (D), GRAMD1 B (E), chr12 - 122277360 (CLIP1) (F), chr17 - 35303285 (G), DEF6 (H), EMX1 (I), HPD (J), PDE4D (K) and SPAG5 (L).
  • Each point in the plots represents a sample, and these are broken down into 5 categories: bulk kidney tissue, human cultured podocytes, renal cortical epithelial cells, human renal proximal tubule epithelial cells and other tissues.
  • the lines represent the median value for each group. For regions of interest that have an assay designed, the location of the assay is highlighted with a grey box.
  • FIG. 5 Native sequence of PAX2 PCR assay region
  • B Bisulfite converted sequence of the methylated top stand
  • Underlined sequences in (B) are the PAX2 forward primer (SEQ ID NO. 5), PAX2 reverse primer (SEQ ID NO. 6) and PAX2 oligonucleotide probe (SEQ ID NO. 7).
  • FIG. 1 Native sequence of GRAMD1 B PCR assay region (A). Bisulfite converted sequence of the methylated top stand (B). Underlined sequences in (B) are the GRAMD1 B forward primer (SEQ ID NO. 12), GRAMD1 B reverse primer (SEQ ID NO. 13) and GRAMD1 B oligonucleotide probe (SEQ ID NO. 14).
  • FIG. 4 Native sequence of DDC PCR assay region (A). Bisulfite converted sequence of the methylated top stand (B). Underlined sequences in (B) are the DDC forward primer (SEQ ID NO. 19), DDC reverse primer (SEQ ID NO. 20) and DDC oligonucleotide probe (SEQ ID NO. 21).
  • FIG. 1 Native sequence of MAST4 PCR assay region (A). Bisulfite converted sequence of the methylated top stand (B). Underlined sequences in (B) are the MAST4 forward primer (SEQ ID NO. 26), MAST4 reverse primer (SEQ ID NO. 27) and MAST4 oligonucleotide probe (SEQ ID NO. 28).
  • FIG. Native sequence of MCF2L PCR assay region (A). Bisulfite converted sequence of the methylated top stand (B). Underlined sequences in (B) are the MCF2L forward primer (SEQ ID NO. 33), MCF2L reverse primer (SEQ ID NO. 34) and MCF2L oligonucleotide probe (SEQ ID NO. 35).
  • FIG. 7 Native sequence of ACTB PCR assay region (A). Bisulfite converted sequence of the bottom strand (B). Underlined sequences in (A) are the ACTB forward primer (SEQ ID NO. 38), ACTB reverse primer (SEQ ID NO. 39) and ACTB oligonucleotide probe (SEQ ID NO. 40). Underlined squences in (B) are ACTB bisulfite forward primer (SEQ ID NO. 43), ACTB bisulfite reverse primer (SEQ ID NO. 44) and ACTB bisulfite oligonucleotide probe (SEQ ID NO. 45).
  • bis UM bisulfite converted unmethylated DNA
  • bis PBMC bisulfite converted peripheral blood mononuclear cell DNA
  • WT PBMC native PBMC DNA
  • Figure 9 A. Graph showing Ct values for 1 mL of ten plasma samples ( ⁇ 30 y.o.) amplified by qPCR for five different kidney-specific assays directed against differentially methylated regions of GRAMD1B, DDC, MAST4, MCF2L and PAX2 genes and also amplified with ACTB to show that DNA is present and to determine the total yield of amplifiable DNA from 1 mL plasma.
  • B. The same data as in A., represented as a % of total cfDNA as determined relative to ACTB amplification.
  • Figure 10 Graph showing concentration of cfDNA in copies per 1 mL of 20 presumed healthy urine samples (26-61 y.o.) amplified by dPCR for five different kidney-specific assays directed against differentially methylated regions of GRAMD1B, DDC, MAST4, MCF2L and PAX2 genes, and also amplified with ACTB to show that DNA is present and to determine the total yield of amplifiable DNA from 1 mL urine.
  • B The same data as in A., showing the mean amount of cfDNA/mL urine relative to age of donor.
  • C The same data as in B., represented as a % of total cfDNA as determined relative to ACTB amplification in age order of donors.
  • FIG. 11 Graphs showing total concentration of kidney specific cfDNA per mL plasma, amplified with kidney-specific assays directed against differentially methylated regions of GRAMD1B, DDC and PAX2 genes, and also amplified with ACTB, in samples taken pre- and post-renal transplant. Samples were collected from 25 individual patients immediately pre-transplant (0 hours), and/or at various times post-transplant (within 24 hours and/or 7 days (168 hours)) depending on the sample.
  • FIG. 12 Graphs showing methylation status of identified probes in different kidney cell types, namely bulk kidney tissue, renal cortical epithelial cells, renal proximal tubule epithelial cells and cultured podocytes.
  • FIG. 13 PCR Assay Development.
  • Figure 14 Graphs showing PAX2, GRAMD1 B and DDC methylation biomarker comparison in urine samples from subjects with various stages of CKD. ACTB used as a control.
  • Figure 15. Graphs showing PAX2, GRAMD1 B and DDC methylation biomarker comparison in urine samples from presumed healthy subjects with no known kidney disease and subjects pre- and post- heart transplant surgery.
  • Figure 16. Graphs showing PAX2, GRAMD1 B and DDC methylation biomarker comparison in plasma samples from presumed healthy subjects with no known kidney disease and subjects pre- and post- heart transplant surgery.
  • FIG. 17 Patient 1 serial testing.
  • Graph A shows total cfDNA
  • Graphs B to D show PAX2, DDC and GRAMD1 B methylation biomarker comparison in urine (left y-axis) and plasma (right y-axis) samples post heart transplant surgery.
  • Graph E provides the standard of care markers for the patient, including creatinine (pmol/mL), eGFR (estimated glomerular filtration rate, ml/min/1.73 m 2 ) and urine output (mL) using a rolling 6-hour average based on hourly readings.
  • FIG. 1 Patient 10 serial testing.
  • Graph A shows total cfDNA
  • Graphs B to D show PAX2, DDC and GRAMD1 B methylation biomarker comparison in urine (left y-axis) and plasma (right y-axis) samples post heart transplant surgery.
  • Graph E provides the standard of care markers for the patient, including creatinine (pmol/mL), and eGFR (estimated glomerular filtration rate, ml/min/1.73 m 2 ) and urine output (mL) using a rolling 6-hour average based on hourly readings.
  • FIG. 19 Graphs showing PAX2 methylation biomarker comparison in urine samples obtained from healthy cats and cats with CKD.
  • Figure 20 Design of methylation specific PCR primers.
  • the native strand of DNA for the differentially methylated region of interest is acquired (top strand) and in silica bisulphite converted either as fully methylated DNA whereby all cytosine (C) residues are converted to thymine (t) except when in the context of CG dinucleotide (middle strand), or fully unmethylated DNA whereby all cytosine (C) residues are converted to thymine (t) including when in the context of CG dinucleotide (bottom strand).
  • Figure 21 DNA alignment between a region of the PAX2 gene for human, cat and dog sequences showing primers (underlined) and probes (bold) in regions of high sequence identity (identity is represented by a star under the aligned sequences).
  • FIG. 22 Analytical PCR results from testing a variety of human PAX2 assays designed within the region hg38; chr10:100,745,582 - 100,829,944
  • FIG. 23 Analytical PCR results from testing a variety of human DDC assays designed within the region hg38; chr7: 50,458,443 - 50,565,405.
  • FIG. 24 Analytical PCR results from testing a variety of human GRAMD1 B assays designed within the region hg38; chr11 :123,358,422 - 123,627,789.
  • Figure 25 Analytical PCR results from testing a variety of human MAST4 assays designed within the region hg38; chr5: 66,596,393 - 67,169,591 .
  • Figure 26 Analytical PCR results from testing a variety of human MCF2L assays designed within the region hg38; chr13: 112,969,214 - 113,099,742. Detailed description
  • an element means one element or more than one element.
  • CpG dinucleotide As used herein, a "CpG dinucleotide”, “CpG methylation site” or equivalent, shall be taken to denote a cytosine linked to a guanine by a phosphodiester bond. CpG dinucleotides are targets for methylation of the cytosine residue and may reside within coding or non-coding nucleic acids.
  • identity refers to a relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, as determined by aligning and comparing the sequences.
  • the comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm.
  • the percent identity between two nucleotide sequences can be determined using the GAP program in the GCG software package, using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1 , 2, 3, 4, 5, or 6.
  • the percent identity between two nucleotide or amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller (CABIOS, 4: 11-17 (1989)) which has been incorporated into the ALIGN program, using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
  • the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (J. Mol. Biol.
  • DNA methylation will be understood to mean the presence of a methyl group added by the action of a DNA methyl transferase enzyme to a cytosine base or bases in a region of nucleic acid e.g. genomic DNA. Accordingly, the term, "methylation status" as used herein refers to the presence or absence of methylation at a specific locus.
  • substantially complementary when used to describe a first nucleotide sequence in relation to a second nucleotide sequence, refers to the ability of an oligonucleotide or polynucleotide comprising the first nucleotide sequence to hybridize to, and form a duplex structure with, an oligonucleotide or polynucleotide comprising the second nucleotide sequence. It will be understood that the sequence of a nucleic acid need not be 100% complementary to that of its target. Conditions under which hybridisation occurs may be stringent, such as 400 mM NaCI, 40 mM PIPES pH 6.4, 1 mM EDTA, 50°C or 70°C for 12-16 hours followed by washing.
  • subject refers to an animal, preferably a mammal, such as a human or non-human including but not limited to members of the classifications of ovine, bovine, equine, porcine, feline, canine, primates and rodents, especially domesticated members of those classifications, such as, but not limited to, cats, sheep, cattle, horses, cats, dogs, pigs, chickens, rats and mice.
  • reference level in the context of the method of the invention refers to a level of a differentially methylated region in a subject that has no or insignificant organ damage, in particular no or insignificant kidney damage.
  • the present invention relates to methods described herein used in relation to human subjects.
  • the present invention relates to the use of methods described herein to detect kidney damage in humans.
  • the present invention relates to, for example, methods described herein used in relation to non-human subjects.
  • the present invention relates to, for example, methods described herein to detect kidney damage in cats and/or dogs.
  • primers and probes suitable for use in the methods described herein could be readily designed to detect DMRs in, for example, at least one locus selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L, PAX2, chr12 - 122277360 (CLIP1), chr17 35303285, DEF6, EMX1 , HPD, PDE4D and SPAG5.
  • kidney DMRs for example GRAMD1 B, DDC, MAST4, MCF2L, PAX2, chr12 - 122277360 (CLIP1), chr17 35303285, DEF6, EMX1 , HPD, PDE4D and SPAG5 from different subject species, such a humans and non-humans exhibit high levels of sequence identity.
  • the skilled person could readily identify kidney DMRs in a range of non-human animals such as, but not limited to, cats, dogs, sheep, cattle, horses, mice, rats, pigs and chickens.
  • Relevant sequence information in relation to loci containing kidney-specific DMRs from human and non-human animals, such as domesticated animals, is set out in Tables 1 to 11 below.
  • FIG. 19 Exemplary support for the identification of kidney-specific DMRs in non-human animals is provided in Figure 19, which shows increased levels of PAX2 methylation biomarker in urine samples obtained from cats with CKD compared with urine obtained from healthy cats.
  • Table 1 Sequence information for PAX2 gene in humans and 9 representative non-human animals including domesticated animals
  • Table 2 Sequence information for GRAMD1 B gene in humans and 9 representative non-human animals including domesticated animals
  • Table 3 Sequence information for DDC gene in humans and 9 representative non-human animals including domesticated animals
  • Table 4 Sequence information for MAST4 gene in humans and 9 representative non-human animals including domesticated animals
  • Table 5 Sequence information for MCF2L gene in humans and 9 representative non-human animals including domesticated animals
  • Table 6 Sequence information for DEF6 gene in humans and 9 representative non-human animals including domesticated animals
  • Table 7 Sequence information for EMX1 gene in humans and 9 representative non-human animals including domesticated animals
  • Table 8 Sequence information for HPD gene in humans and 9 representative non-human animals including domesticated animals
  • Table 9 Sequence information for PDE4D gene in humans and 9 representative non-human animals including domesticated animals
  • Table 10 Sequence information for SPAG5 gene in humans and 9 representative non-human animals including domesticated animals
  • Table 11 Sequence information for CLIPI gene in humans and 9 representative non-human animals including domesticated animals
  • each range should be considered to encompass subranges therein.
  • the description of a range such as from 1 to 6 should be considered to include subranges such as from 1 to 5, from 2 to 4, from 2 to 6 and so on.
  • the description of a range of between 1 and 6 should be considered to include subranges such as between 2 and 5, between 1 and 3, between 3 and 6 and so on.
  • Organ and tissue damage leading to organ- or tissue-specific cell death results in an increased concentration of organ- or tissue-specific DNA in the cfDNA population.
  • the present inventors have found epigenetic signatures within different organs, tissues and even cell types that can be used as markers to detect organ, tissue or cell damage from a sample of cfDNA. For example, an increased concentration of kidney-specific epigenetic markers within cfDNA may be indicative of kidney damage resulting from cell death within the kidney.
  • the methods described herein may be used to diagnose a disease or condition or disorder associated with cell death. The methods may also be used to prognose the likelihood of an event occurring. For example, the methods described herein may be used to prognose kidney failure in a subject.
  • the methods described herein are not limited to any particular organ or tissue.
  • the methods may be used to detect damage of the kidney, liver, spleen, prostate, heart, muscle, lungs, brain, small intestine, large intestine, bladder, pancreas, adrenal glands, breast, colon, pancreas, bone, placenta or skin, or a tissue or cell-type thereof.
  • the damage may be caused by disease, infection or trauma.
  • the methods described herein detect epigenetic markers in cfDNA from dead neurons (indicative of traumatic brain injury, amyotrophic lateral sclerosis, stroke, Alzheimer's disease, Parkinson's disease or brain tumors), dead pancreatic acinar cells (indicative of pancreatic cancer or pancreatitis), dead lung cells (indicative of lung pathologies including lung cancer), dead adipocytes (indicative of altered fat turnover), dead hepatocytes (indicative of liver failure, liver disease or liver toxicity), dead cardiomyocytes (indicative of cardiac disease or graft failure in the case of cardiac transplantation), dead skeletal muscle cells (indicative of muscle injury and myopathies), dead oligodendrocytes (indicative of relapsing multiple sclerosis, white matter damage in amyotrophic lateral sclerosis or glioblastoma), dead placental cells (indicative of pre-eclampsia or placental abruption)
  • the methods described herein are used to detect kidney damage. Damage to the kidney may arise, for example, from acute kidney injury (AKI) or chronic kidney disease (CKD). At-risk groups for whom regular screening may be particularly beneficial include diabetics, subjects with high blood pressure, subjects with polycystic kidney disease, transplant recipients and so on.
  • AKI acute kidney injury
  • CKD chronic kidney disease
  • At-risk groups for whom regular screening may be particularly beneficial include diabetics, subjects with high blood pressure, subjects with polycystic kidney disease, transplant recipients and so on.
  • Kidney disease is a major health problem that represents an interlinked spectrum of AKI and CKD.
  • AKI is associated with high morbidity, mortality, prolonged hospital stay and progression to CKD.
  • Patients with CKD can progress to End Stage Renal Disease (ESRD) where they require dialysis or a kidney transplant.
  • ESRD End Stage Renal Disease
  • Kidney disease has a large, measurable cost to the health system and is disproportionately prevalent in Native Australians, lower socio-economic groups, the elderly and people in rural/remote locations. Kidney disease is under-diagnosed and most people are unaware of its presence until symptoms manifest.
  • the ability to detect these conditions earlier, in populations at greater risk and in patients with no overt clinical symptoms, will enable quicker intervention to reduce further kidney damage and reduce the morbidity and mortality associated with AKI/CKD.
  • the present disclosure provides methods that are useful in the early detection of AKI and CKD.
  • the methods described herein may also be used to detect tissue or organ damage following a tissue or organ transplant.
  • the methods may be used to detect kidney damage following a kidney transplant.
  • the methods may identify early signs of organ rejection.
  • the methods may also be used to detect tissue or organ damage following a particular treatment.
  • the methods may be used to detect kidney damage following cardiothoracic surgery or renal replacement therapy.
  • the methods described herein do not rely upon detecting unique DNA sequences, and as such, they are not limited to settings in which the genome of one subject is to be distinguished from the genome of another subject (eg, following an organ or tissue transplant).
  • the presently disclosed methods can be used to detect damage of a subject’s own organ.
  • the subject and the organ are preferably autologous.
  • the epigenetic markers described herein may be organ-specific, tissue-specific or cell-specific, and in that regard, the methods of the present disclosure may be used to detect organ, tissue or cell damage.
  • the present inventors have identified epigenetic markers (eg, methylation in MAST4 and DDC) which are enriched in renal proximal tubule epithelial cells relative to other cells of the kidney and other organs of the body. Those markers may be used to diagnose conditions associated with or caused by damage to renal proximal tubule epithelial cells, such as ischemic reperfusion injury.
  • Renal Proximal Tubule Epithelial Cells have a large abundance of mitochondria with a heavy dependence on oxidative phosphorylation, making them vulnerable to injury and early markers for ischemic reperfusion injury through cell death. Damage to the RPTECs can also result in the formation of atubular glomeruli, leading to CKD. The ability to detect RPTEC specific cell death will improve early detection and location specific injury relevant to injury from surgery and disease.
  • the present disclosure provides a method of detecting renal proximal tubule epithelial cell damage in a subject, the method comprising detecting methylation status at MAST4 or DDC in cfDNA obtained from a biological sample of the subject, wherein presence of methylated MAST4 or DDC in cfDNA is indicative of renal proximal tubule epithelial cell damage. It will be understood that increased levels of methylated MAST4 and/or DDC DNA in cfDNA obtained from a subject may be indicative that the subject is suffering from renal proximal tubule epithelial cell damage.
  • the present disclosure provides a method of diagnosing ischemic reperfusion injury in a subject, the method comprising detecting methylation status at MAST4 or DDC in cfDNA obtained from a biological sample of the subject.
  • the method of the invention uses a combination of kidney differentially methylated regions to obtain a measurement of kidney injury.
  • the present invention provides kidney differentially methylated regions that correlate with particular kidney cells.
  • PAX2 in urine serves as a useful marker for general kidney damage.
  • Pax2 is not an optimal classifier for stage two samples in CKD.
  • GRAMD1 B and DDC which correlate to kidney podocytes and renal proximal tubule cells, offer more effective options for detecting kidney damage issues.
  • PAX2 is likely to be susceptible to variability resulting from inflammation caused by, for example, infections.
  • kidney transplant it is known that the BK virus can cause an increase in kidney cfDNA in urine when measuring dd-cfDNA, which is expected as the infection is kidney-based. Consequently, the measurement of tubular markers is likely to provide a more robust assessment as they are less likely to be affected by the infection.
  • measuring PAX2 enables a general determination of an issue in the kidney, other kidney DMRs provide a more specific indication of kidney cell damage. For example, detection of elevated levels of GRAMD1 B indicates kidney podocytes damage and detection of elevated levels of DDC indicates renal proximal tubule cell damage.
  • the methods described herein may also be useful in detecting proliferative diseases such as cancer. Such diseases may be associated not only with increased cell proliferation but also with increased cell damage or cell death.
  • the proliferating cells themselves eg, tumor cells
  • the proliferating cells may die over time, releasing DNA that can be detected in cfDNA using the methods described herein.
  • the proliferating cells may cause damage or death to proximal or distal cells which thus release DNA that can be detected in cfDNA using the methods described herein.
  • the present disclosure also contemplates treatment of subjects found to be suffering from, or at risk of, organ or tissue damage. Treatment may include, for example, administration of a medicament, surgery, chemotherapy, lifestyle change, dietary change or physical therapy.
  • the present disclosure provides a method of detecting organ damage in a subject, the method comprising: detecting an organ-specific epigenetic marker in cfDNA obtained from a biological sample of the subject, wherein the presence of the epigenetic marker in the cfDNA is indicative of organ damage; and, if organ damage is detected, administering to the subject a treatment for the organ damage.
  • the present disclosure provides a method of treating a subject suffering from organ damage or at risk of suffering from organ damage, wherein the organ damage has been detected by a method comprising detecting an organ-specific epigenetic marker in cfDNA obtained from a biological sample of the subject, wherein the presence of the epigenetic marker in the cfDNA is indicative of organ damage.
  • the epigenetic markers of the present disclosure are cell-specific, tissue-specific or organspecific in the sense that they are enriched in that cell, tissue or organ relative to other cells, tissues or organs of the body.
  • the epigenetic marker is at least about 5% more abundant, such as at least about 10% more abundant, or at least about 15% more abundant, at least about 20% more abundant, at least about 25% more abundant, at least about 30% more abundant, at least about 35% more abundant, at least about 40% more abundant, at least about 45% more abundant, at least about 50% more abundant, at least about 55% more abundant, at least about 60% more abundant, at least about 65% more abundant, at least about 70% more abundant, at least about 75% more abundant, at least about 80% more abundant, at least about 85% more abundant, at least about 90% more abundant, at least about 95% more abundant or at least about 100% more abundant in the cell, tissue or organ of interest relative to other cells, tissues or organs of the body.
  • the epigenetic marker is at least 2-fold more abundant, at least 3-fold more abundant, at least 4-fold more abundant, at least 5-fold more abundant, at least 6-fold more abundant, at least 7-fold more abundant, at least 8-fold more abundant, at least 9-fold more abundant, at least 10-fold more abundant, at least 11-fold more abundant, at least 12-fold more abundant, at least 13-fold more abundant, at least 14-fold more abundant or at least 15-fold more abundant in the cell, tissue or organ of interest relative to other cells, tissues or organs of the body. In some examples, the epigenetic marker is only detectable in the cell, tissue or organ of interest.
  • epigenetic markers may be used to identify specific cell-, tissue- or organ-types. Suitable epigenetic markers may include acetylation status of DNA or histones, or methylation status of DNA or histones. In some examples, the epigenetic marker is selected from the group consisting of a DNA modification, a histone modification and nucleosome positioning.
  • nucleosome positioning is determined by a nucleosome positioning assay.
  • Histone modifications may be detected by a pull-down assay using antibodies specific for a histone modification.
  • the antibodies may be specific for histone methylation, acetylation, phosphorylation, ubiquitylation, GIcNAcylation, citrullination, krotonilation, or isomerization.
  • the histone methylation-specific antibodies comprise antibodies against H3K4Me1 , H3K4Me2, H3K4Me3, or H3K36Me3 modifications.
  • the epigenetic marker used in the methods of the present disclosure is DNA methylation status at one or more DMRs within the cfDNA.
  • a DMR may be unmethylated in the heart but methylated in other parts of the body.
  • the DMR is methylated in the kidney but unmethylated in other parts of the body.
  • the amount of methylated DNA at the DMR that is present in cfDNA of a subject may be proportional to the level of organ damage experienced by the subject.
  • Methylation status may be detected at one or more CpG dinucleotides.
  • one epigenetic marker may have methylation at one CpG dinucleotide, two CpG dinucleotides, three CpG dinucleotides, four CpG dinucleotides, five CpG dinucleotides, six CpG dinucleotides, seven CpG dinucleotides, eight CpG dinucleotides, nine CpG dinucleotides, 10 CpG dinucleotides, 11 CpG dinucleotides, 12 CpG dinucleotides, 13 CpG dinucleotides, 14 CpG dinucleotides, 15 CpG dinucleotides, 16 CpG dinucleotides, 17 CpG dinucleotides, 18 CpG dinucleotides, 19 CpG dinucleotides, or at least 20 CpG dinucle
  • the cfDNA may be treated with bisulfite and sequenced or assayed using a PCR technique.
  • Bisulfite conversion typically involves treating DNA with a bisulfite such as sodium bisulfite, leading to deamination of unmethylated cytosines into uracils, while methylated cytosines (both 5-methylcytosine and 5- hydroxymethylcytosine) remain unchanged. This is illustrated in Figure 20.
  • the DNA can then be amplified by PCR where the uracils are converted to thymines.
  • Bisulfite converted DNA can be analysed for methylation status using primers that differentiate between methylated and unmethylated sequences.
  • Primers may be designed such that amplification only occurs (or is substantially more efficient) when the template is derived from either methylated or unmethylated DNA.
  • probes may be designed that specifically hybridise to bisulfite-converted DNA that is derived from either methylated or unmethylated DNA. It will be understood that following bisulfite- conversion of DNA, the two strands are often no longer complementary to each other, meaning that primers and probes to either strand may be designed.
  • the methylation status is detected using quantitative PCR (qPCR), digital PCR (dPCR) or digital droplet PCR (ddPCR). These techniques are described in Shemer, R.
  • Unmethylated cytosine nucleotides can also be enzymatically converted to uracil nucleotides, for example, using NEBNext’s Enzymatic Methyl-seq Kit.
  • the Methyl-seq Kit uses TET2 to oxidise 5-methylcytosine and 5- hydroxymethylcytosine, thereby protecting those methylated cytosines from deamination by apolipoprotein B mRNA-editing enzyme, catalytic polypeptide (APOBEC).
  • APOBEC catalytic polypeptide
  • the methylation status may be detected using a nanopore sequencing technology.
  • the nanopore sequencing technology may detect native CpG methylation in cfDNA without prior bisulfite treatment.
  • the amplification product of bisulfite-converted DNA may be sequenced to determine the methylation status of the template - comparing the sequence of the converted DNA to untreated DNA creates a methylation profile of the amplified region.
  • the presence of a mutated or nonmutated nucleotide in a bisulfite-treated sample may also be detected using pyrosequencing, such as, for example, as described in Uhlmann et al., Electrophoresis, 23: 4072-4079, 2002.
  • this method is a form of real-time sequencing that uses a primer that hybridizes to a site adjacent or close to the site of a cytosine that is methylated.
  • each of four modified deoxynucleotide triphosphates are added separately according to a predetermined dispensation order. Only an added nucleotide that is complementary to the bisulfite treated sample is incorporated and inorganic pyrophosphate (PPi) is liberated. The PPi then drives a reaction resulting in production of detectable levels of light.
  • PPi inorganic pyrophosphate
  • the presence of a non-mutated nucleic sequence may also be detected using combined bisulfite restriction analysis (COBRA) essentially as described in Xiong and Laird, Nucl Acids Res., 25: 2532-2534, 2001.
  • COBRA combined bisulfite restriction analysis
  • This method exploits the differences in restriction enzyme recognition sites between methylated and unmethylated nucleic acid after bisulfite treatment.
  • Methylation specific microarrays (MSO) are also useful for differentiating between a mutated and non-mutated sequence.
  • a suitable method is described, for example, in Adorjin et al, Nucl. Acids Res., 30: e21 , 2002.
  • the cfDNA may be used as a template directly in a methylation-sensitive PCR assay.
  • Methylation-sensitive PCR may rely upon the use of a methylation-sensitive restriction enzyme which cuts either methylated or unmethylated DNA but not both.
  • exemplary methylationsensitive restriction enzymes include Aatll, Aval, Cfol, Eco47llll, Hpal, Hpall, Mlul, Nael, Narl, Notl, Nrul, Pvul, Sacll, Smal, SnaBI and Xhol.
  • Hpal for example, recognises and cuts GTT
  • DNA may be treated with a methylation-sensitive restriction enzyme and subsequently used as a template for PCR amplification using primers flanking the recognition and cleavage site of the methylation-sensitive restriction enzyme.
  • the PCR assay may be quantitative or semi-quantitative.
  • US Patent No. 7,229,759 also describes a technology (sometimes referred to as “methylight”) that may be used to detect methylation status.
  • the method of detecting methylation status does not involve genome sequencing. In some examples, the method does not involve DNA sequencing. PCR-based assays may be cheaper and faster than sequencing-based methods. Moreover, certain biological samples such as urine may be better suited to PCR-based techniques rather than sequencing-based methods due to issues such as cfDNA fragmentation.
  • probes and/or primers for use in, for example, PCR or hybridisation are known in the art and described, for example, in Dieffenbach and Dveksler (Eds) (In: PCR Primer: A Laboratory Manual, Cold Spring Harbor Laboratories, NY, 1995). Furthermore, several software packages are publicly available that design probes and/or primers for a variety of assays.
  • the primers and/or probes comprise fluorescent labels. The fluorescent signal from the probe may be measured as the readout and tissue composition of the cfDNA may be inferred from the readout.
  • the epigenetic marker used in the methods of the present disclosure is DNA methylation status within one or more DMRs of the cfDNA.
  • the epigenetic marker is kidney-specific. Kidney-specific epigenetic markers may include methylated DMRs at one or more loci selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L, PAX2, chr12 - 122277360 (CLIP1), chr17 - 35303285, DEF6, EMX1 , HPD, PDE4D and SPAG5.
  • the DMRs are located at one locus selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L, PAX2, chr12 - 122277360 (CLIP1), chr17 35303285, DEF6, EMX1 , HPD, PDE4D and SPAG5. In some examples, the DMRs are located at more than one locus selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L, PAX2, chr12 - 122277360 (CLIP1), chr17 35303285, DEF6, EMX1 , HPD, PDE4D and SPAG5.
  • the DMRs are located at one or more loci selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L and PAX2. Sequences from these loci are set forth in Table 12, but the skilled person will understand that natural polymorphisms and allelic variation will exist between individuals.
  • the DMRs are located at one locus selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L and PAX2.
  • at least one DMR is located in PAX2.
  • at least one DMR comprises the sequence set forth in SEQ ID NO. 1 or SEQ ID NO. 2 or a sequence having at least 90% identity to SEQ ID NO. 1 or SEQ ID NO. 2.
  • At least one DMR is located in GRAMD1 B. In some examples, at least one DMR comprises the sequence set forth in SEQ ID NO. 8 or SEQ ID NO. 9 or a sequence having at least 90% identity to SEQ ID NO. 8 or SEQ ID NO. 9. In some examples, at least one DMR is located in DDC. In some examples, at least one DMR comprises the sequence set forth in SEQ ID NO. 15 or SEQ ID NO. 16 or a sequence having at least 90% identity SEQ ID NO. 15 or SEQ ID NO. 16. In some examples, at least one DMR is located in MAST4. In some examples, at least one DMR comprises the sequence set forth in SEQ ID NO. 22 or SEQ ID NO. 23 or a sequence having at least 90% identity to SEQ ID NO.
  • At least one DMR is located in MCF2L. In some examples, at least one DMR comprises the sequence set forth in SEQ ID NO. 29 or SEQ ID NO. 30 or a sequence having at least 90% identity to SEQ ID NO. 29 or SEQ ID NO. 30.
  • the DMRs are located at two loci selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L and PAX2.
  • the DMRs may be located at: GRAMD1 B and DDC; GRAMD1B and MAST4; GRAMD1 B and MCF2L; GRAMD1 B and PAX2; DDC and MAST4; DDC and MCF2L; DDC and PAX2; MAST4 and MCF2L; MAST4 and PAX2; or MCF2L and PAX2.
  • the DMRs are located at three loci selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L and PAX2.
  • the DMRs may be located at: GRAMD1 B, DDC and MAST4; GRAMD1 B, DDC and MCF2L; GRAMD1 B, DDC and PAX2; GRAMD1 B, MAST4 and MCF2L; GRAMD1 B, MAST4 and PAX2; GRAMD1 B, MCF2L and PAX2; DDC, MAST4 and MCF2L; DDC, MAST4 and PAX2; DDC, MCF2L and PAX2; or MAST4; MCF2L and PAX2.
  • the DMRs are located at four loci selected from the group consisting of GRAMD1B, DDC, MAST4, MCF2L and PAX2.
  • the DMRs may be located at GRAMD1 B, DDC, MAST4 and MCF2L; GRAMD1 B, DDC, MAST4 and PAX2; GRAMD1B, MAST4, MCF2L and PAX2; GRAMD1 B, DDC, MCF2L and PAX2; or DDC, MAST4, MCF2L and PAX2.
  • the DMRs are located at GRAMD1 B, DDC, MAST4, MCF2L and PAX2.
  • the methylation status at each locus may be detected in separate, singleplex assays, or the methylation status at all loci may be detected in a single, multiplex assay.
  • the DMRs may be located at two loci and the methylation status may be detected using a duplex assay. In another example, the DMRs are located at three loci and the methylation status may be detected using a triplex assay.
  • the method may, for example, comprise detecting the methylation status at GRAMD1 B, DDC and PAX2 using a triplex assay.
  • the DMRs are located at four loci and the methylation status may be detected using a quadruplex assay.
  • the DMRs are located at five loci and the methylation status may be detected using a pentaplex assay.
  • a DMR may comprise one methylation site or multiple methylation sites. DMRs may be adjacent to each other on the same chromosome, or they may be located distally apart on a chromosome or on different chromosomes.
  • the present disclosure also provides isolated nucleic acids corresponding to a tissue- or organ-specific DMR, optionally wherein the nucleic acid is bisulfite-treated.
  • the present disclosure provides an isolated nucleic acid having a sequence derived from or corresponding to GRAMD1 B, DDC, MAST4, MCF2L or PAX2, or a portion of GRAMD1 B, DDC, MAST4, MCF2L or PAX2.
  • the portion is preferably at least 30 nucleotides in length, such as between about 30 nucleotides and 600 nucleotides, or between about 30 nucleotides and 500 nucleotides, or between about 30 nucleotides and 400 nucleotides, or between about 30 nucleotides and 350 nucleotides, or between about 30 nucleotides and 300 nucleotides, or between about 30 nucleotides and 250 nucleotides, or between about 30 nucleotides and 200 nucleotides, or between about 30 nucleotides and 150 nucleotides, or between about 40 nucleotides and 150 nucleotides, or between about 40 nucleotides and 100 nucleotides, or between about 50 nucleotides and 100 nucleotides in length.
  • the present disclosure provides an isolated nucleic acid having a sequence that is at least 80% identical, or at least 85% identical, or at least 90% identical, or at least 95% identical or 100% identical to the sequence set forth in any one of SEQ ID NOs. 1 to 35.
  • the present disclosure provides an isolated nucleic acid produced by bisulfite-treatment of a nucleic acid molecule having a sequence that is at least 80% identical, or at least 85% identical, or at least 90% identical, or at least 95% identical or 100% identical to the sequence set forth in SEQ ID NO. 1 , SEQ ID NO. 2, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 22, SEQ ID NO. 23, SEQ ID NO. 29 or SEQ ID NO. 30.
  • the nucleic acid is bisulfite-treated.
  • the present disclosure provides a bisulfite-treated nucleic acid having a sequence that is at least 80% identical, or at least 85% identical, or at least 90% identical, or at least 95% identical or 100% identical to the sequence set forth in SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7,
  • SEQ ID NO. 10 SEQ ID NO. 11 , SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 17,
  • SEQ ID NO. 18 SEQ ID NO. 19
  • SEQ ID NO. 20 SEQ ID NO. 21
  • SEQ ID NO. 24 SEQ ID NO. 25
  • SEQ ID NO. 26 SEQ ID NO. 27, SEQ ID NO. 28, SEQ ID NO. 31 , SEQ ID NO. 32, SEQ ID NO. 33,
  • the bisulfite-treated nucleic acid is at least 30 nucleotides in length, such as between about 30 nucleotides and 600 nucleotides, or between about 30 nucleotides and 500 nucleotides, or between about 30 nucleotides and 400 nucleotides, or between about 30 nucleotides and 350 nucleotides, or between about 30 nucleotides and 300 nucleotides, or between about 30 nucleotides and 250 nucleotides, or between about 30 nucleotides and 200 nucleotides, or between about 30 nucleotides and 150 nucleotides, or between about 40 nucleotides and 150 nucleotides, or between about 40 nucleotides and 100 nucleotides, or between about 50 nucleotides and 100 nucleotides in length.
  • An assessment as to whether the subject is suffering from, or at risk of, tissue or organ damage may be made by comparing the level of the epigenetic marker to a reference level, or by monitoring the level of the epigenetic marker over time.
  • a reference level of the epigenetic marker in cfDNA may be used as a baseline against which the level of the epigenetic marker in a cfDNA sample is compared.
  • the reference level may represent the concentration of the epigenetic marker that is expected in the cfDNA of a healthy individual or a group or population of healthy individuals.
  • a higher or lower concentration of the epigenetic marker in the sample cfDNA relative to the reference level may indicate that the subject is suffering from, or at risk of, tissue or organ damage.
  • the reference level may be based on studies conducted on cfDNA taken from healthy individuals, or it may be based on the concentration of the epigenetic marker in cfDNA from the subject at a defined point in time (eg, prior to a particular treatment).
  • the reference level may be based on a data set comprising levels of the epigenetic marker in a healthy subject or a population of healthy individuals.
  • a difference of at least about 5% in the level of the epigenetic marker in the sample cfDNA compared to the reference level may be indicative of tissue or organ damage.
  • a difference of at least about 10%, such as at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95% or at least about 100% may be indicative of tissue or organ damage.
  • organ or tissue damage may be indicated when the amount of the epigenetic marker present in cfDNA of the sample is about 5% higher than the amount present in the reference cfDNA. In some examples, organ or tissue damage may be indicated when the amount of the epigenetic marker present in cfDNA of the sample is at least about 10% higher, such as at least about 15% higher, at least about 20% higher, at least about 25% higher, at least about 30% higher, at least about 35% higher, at least about 40% higher, at least about 45% higher, at least about 50% higher, at least about 55% higher, at least about 60% higher, at least about 65% higher, at least about 70% higher, at least about 75% higher, at least about 80% higher, at least about 85% higher, at least about 90% higher, at least about 95% higher or at least about 100% higher than the amount present in the reference cfDNA.
  • organ or tissue damage may be indicated when the amount of the epigenetic marker present in cfDNA of the sample is at least about 2- fold higher, such as at least about 3-fold higher, at least about 4-fold higher, at least about 5-fold higher, at least about 6-fold higher, at least about 7-fold higher, at least about 8-fold higher, at least about 9-fold higher or at least about 10-fold higherthan the amount present in the reference cfDNA.
  • the reference level of the epigenetic marker may be zero (not detectable) and the detectable presence of the epigenetic marker in the sample cfDNA may be indicative of tissue or organ damage.
  • the level of the epigenetic marker is measured over time. A subject may be monitored, for example, by taking biological samples from the subject over time and measuring the level of the epigenetic marker in cfDNA from each biological sample. An increase in the concentration of the epigenetic marker in cfDNA over time may indicate that the subject is suffering from, or at risk of, tissue or organ damage.
  • the methods described herein may be performed on a subject of any age, but cell damage may be more prevalent in older subjects compared to younger subjects.
  • cell-, tissue- or organ-specific epigenetic markers may be present at higher concentrations in older subjects relative to younger subjects.
  • the present disclosure provides a method of detecting organ damage in a subject, wherein the subject is at least 5 years old.
  • the subject is at least 10 years old, or at least 15 years old, or at least 20 years old, or at least 25 years old, or at least 30 years old, or at least 35 years old, or at least 40 years old, or at least 45 years old, or at least 50 years old, or at least 55 years old, or at least 60 years old, or at least 65 years old.
  • Epigenetic data can be combined and made more clinically useful through the use of various formulae, including statistical classification algorithms and others, combining and in many cases extending the performance characteristics of the combination beyond that of any individual data point. These specific combinations show an acceptable level of diagnostic/prognostic accuracy, and, when sufficient information from one or more markers is combined in a trained formula, may reliably achieve a high level of diagnostic/prognostic accuracy transportable from one population to another.
  • any suitable formula may be used to combine epigenetic marker results into indices or indexes useful in the methods of the disclosure.
  • indices may indicate, among the various other indications, the probability, likelihood, absolute or relative risk, time to or rate of organ damage, conversion from one to another disease states, or make predictions of future epigenetic marker measurements of organ or tissue damage. This may be for a specific time period or horizon, or for remaining lifetime risk, or simply be provided as an index relative to another reference subject population.
  • the actual model type or formula used may itself be selected from the field of potential models based on the performance and diagnostic accuracy characteristics of its results in a training population.
  • the specifics of the formula itself may commonly be derived from marker results in the relevant training population.
  • such formula may be intended to map the feature space derived from one or more marker inputs to a set of subject classes (eg, useful in predicting class membership of subjects as normal, at risk of organ damage, or responding/not-responding to treatment), to derive an estimation of a probability function of risk using a Bayesian approach (eg, the risk of organ damage or recurrence event), or to estimate the class-conditional probabilities, then use Bayes' rule to produce the class probability function.
  • subject classes eg, useful in predicting class membership of subjects as normal, at risk of organ damage, or responding/not-responding to treatment
  • Bayesian approach eg, the risk of organ damage or recurrence event
  • the index can be transmitted or provided to a third party, e.g., a medical practitioner for assessment.
  • the index may be used by the practitioner to assess whether or not additional diagnostic methods are required, e.g., biopsy and histological analysis and/or other assays, or a change in treatment or commencement of treatment.
  • Knowledge-based computer software and hardware for implementing an algorithm of the disclosure also form part of the present disclosure.
  • the present disclosure also provides software or hardware programmed to implement an algorithm that processes data obtained by performing the method of the disclosure via a univariate or multivariate analysis to provide a damage index value and provide or permit a diagnosis of organ or tissue damage.
  • a method of the disclosure may be used in existing knowledge-based architecture or platforms associated with pathology services. For example, results from a method described herein are transmitted via a communications network (eg, the internet) to a processing system in which an algorithm is stored and used to generate a predicted posterior probability value which translates to the index of damage probability which is then forwarded to an end user in the form of a diagnostic or predictive report.
  • the method of the disclosure may, therefore, be in the form of a kit or computer-based system which comprises the reagents necessary to detect the level of the epigenetic marker(s) and the computer hardware and/or software to facilitate determination and transmission of reports to a clinician.
  • the present disclosure permits integration of an assay into existing or specifically developed pathology architecture or platform systems.
  • the present disclosure contemplates a method of allowing a user to determine the status of a subject with respect to organ damage, the method comprising: (a) receiving sample epigenetic data in the form of a level of an organ-specific epigenetic marker in cfDNA obtained from a biological sample of the subject relative to reference epigenetic data, optionally in combination with another marker of organ damage; (b) processing the sample epigenetic data via univariate and/or multivariate analysis to provide a damage index value; (c) determining the status of the subject in accordance with the damage index value in comparison with predetermined values; and (d) transferring an indication of the status of the subject to the user via a communications network.
  • the method further comprises: (i) having the user determine the data using a remote end station; and (ii) transferring the data from the end station to a base station via the communications network.
  • the base station may include first and second processing systems, in which case the method may comprise: (a) transferring the data to the first processing system; (b) transferring the data to the second processing system; and (c) causing the first processing system to perform the univariate or multivariate analysis to generate the damage index value.
  • the method may also comprise: (a) transferring the results of the univariate or multivariate analysis function to the first processing system; and (b) causing the first processing system to determine the status of the subject.
  • Biological samples from which cfDNA may be obtained may include saliva, blood or serum or plasma, urine, semen, vitreous fluid, lymph fluid, synovial fluid, follicular fluid, gastric fluid, intestinal fluid, bile, tumour fluid, interstitial fluid, amniotic fluid, mucus, breast milk, pleural fluid, sweat, tears, stool, serum or cerebro-spinal fluid.
  • saliva blood or serum or plasma
  • urine semen
  • vitreous fluid lymph fluid
  • synovial fluid follicular fluid
  • gastric fluid intestinal fluid
  • bile tumour fluid
  • interstitial fluid interstitial fluid
  • amniotic fluid mucus
  • mucus mucus
  • breast milk pleural fluid
  • sweat tears, stool, serum or cerebro-spinal fluid
  • Methods for obtaining a biological sample from a subject include, for example, surgery, biopsy or collection of a bodily fluid, for example, by paracentesis or thoracentesis or collection of, for example, blood or a fraction thereof.
  • the methods of the present disclosure include obtaining a biological sample comprising cfDNA from a subject, and optionally isolating the cfDNA from the biological sample.
  • the biological sample is a liquid.
  • Some biological samples may be better suited than others for detecting organ or tissue damage depending upon the particular organ or tissue in question.
  • urine is used as a biological sample to detect kidney damage.
  • blood or plasma is used as a biological sample to detect heart damage.
  • the DMR may be present in a biological sample of a healthy subject at a concentration of at least about 3.3 pg of single stranded DNA /mL, such as at least about 4 pg/mL, or at least about 5 pg/mL, or at least about 10 pg/mL, or at least about 20 pg/mL, or at least about 30 pg/mL, or at least about 40pg/mL, or at least about 50 pg/mL, or at least 75 pg/mL, or at least about 100 pg/mL, or at least about 125 pg/mL, or at least about 150 pg/mL, or at least about 175 pg/mL, or at least about 200 pg/mL, or at least about 225 pg/mL, or at least about 250 pg/mL, or at least about 275 pg/mL, or at least about 300 pg/mL, or at least
  • the DMR may be present in a biological sample of a healthy subject at a concentration of at least about 1 copy/mL, such as at least about 5 copies/mL, or at least about 10 copies/mL, or at least about 15 copies/mL, or at least about 20 copies/mL, or at least about 25 copies/mL, or at least about 50 copies/mL, or at least about 75 copies/mL, or at least about 100 copies/mL, or at least about 150 copies/mL, or at least about 200 copies/mL, or at least about 250 copies/mL, or at least about 300 copies/mL, or at least about 350 copies/mL, or at least about 400 copies/mL, or at least about 450 copies/mL, or at least about 500 copies/mL, or at least about 600 copies/mL, or at least about 700 copies/mL, or at least about 800 copies/mL, or at least about 900 copies/mL, or at least about 1000 copies/mL.
  • the proportion of the cfDNA in a biological sample of a healthy subject that corresponds to the epigenetic marker is 1%; for example, in circumstances where the epigenetic marker is methylated DNA at locus A, about 1 % of the locus A DNA molecules in the cfDNA are methylated.
  • the proportion of the cfDNA in a biological sample of a healthy subject that corresponds to the tissue- or organ-specific epigenetic marker is less than about 75%, such as less than about 70%, or less than about 65%, or less than about 60%, or less than about 55%, or less than about 50%, or less than about 45%, or less than about 40%, or less than about 35%, or less than about 30%, or less than about 25%, or less than about 20%, or less than about 15%, or less than about 10%, or less than about 5%, or less than about 1%, or less than about 0.1%.
  • the proportion of the cfDNA that corresponds to the epigenetic marker may be lower where the marker is cell-type-specific or tissue-specific, and higher where the marker is organ-specific. It will also be understood that the proportion of the cfDNA that corresponds to the epigenetic marker may increase when there is tissue or organ damage.
  • Method 1 A method of diagnosing organ damage in a subject the method comprising detecting an organ-specific epigenetic marker in cfDNA obtained from a biological sample of the subject, wherein the presence of the epigenetic marker in the cfDNA is indicative of organ damage.
  • Method 2 A method of detecting organ damage in a subject, the method comprising: a) obtaining a biological sample comprising cfDNA from the subject; and b) detecting an organ-specific epigenetic marker in the cfDNA, wherein the presence of the epigenetic marker in the cfDNA is indicative of organ damage.
  • Method 3 The method of Method 1 or Method 2 wherein the method comprises detecting an increase in the level of the epigenetic marker relative to a reference level.
  • Method 4 The method of Method 1 or Method 2 wherein the method comprises detecting an increase in the level of the epigenetic marker over time.
  • Method 5 The method of any one of Methods 1 to 4 wherein the epigenetic marker is DNA methylation status at a differentially methylated region of the cfDNA.
  • Method 6 The method of any one of Methods 1 to 5 wherein the method comprises detecting cfDNA methylation status at more than one differentially methylated region.
  • Method 7 The method of Method 6 wherein the methylation status is determined at more than one differentially methylated region using a multiplex assay.
  • Method 8 The method of any one of Methods 5 to 7 wherein the methylation status is determined by a method that does not involve DNA sequencing.
  • Method 9 The method of any one of Methods 5 to 8 wherein the methylation status is determined by treating the cfDNA with bisulfite and amplifying the differentially methylated region using polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • Method 10 The method of Method 9 wherein the PCR is digital PCR (dPCR), digital droplet PCR (ddPCR) or quantitative PCR (qPCR).
  • dPCR digital PCR
  • ddPCR digital droplet PCR
  • qPCR quantitative PCR
  • Method 11 The method of any one of Methods 1 to 10 wherein the subject and the organ are autologous.
  • Method 12 The method of any one of Methods 1 to 11 wherein the organ is a kidney.
  • Method 13 The method of any one of Methods 1 to 12 wherein the organ damage is associated with acute kidney injury, chronic kidney disease or kidney transplant rejection.
  • Method 14 The method of any one of Method 1 to 12 wherein the organ damage is associated with chemotherapy or radiotherapy.
  • Method 15 The method of any one of Methods 1 to 14 wherein the biological sample is urine.
  • Method 16 The method of any one of Methods 5 to 15 wherein the differentially methylated region is located at one or more loci selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L, PAX2, chr12 - 122277360 (CLIP1), chr17 - 35303285, DEF6, EMX1 , HPD, PDE4D and SPAG5.
  • Method 17 The method of any one of Methods 5 to 16 wherein the differentially methylated region is located at one or more loci selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L and PAX2.
  • Method 18 The method of any one of Methods 5 to 17 wherein the differentially methylated region comprises a sequence having at least 90% identity to any one or more of SEQ ID NO. 1 , SEQ ID NO. 2 SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 22, SEQ ID NO. 23, SEQ ID NO. 29 or SEQ ID NO. 30.
  • Method 19 The method of any one of Methods 1 to 18 wherein the method specifically detects damage to a defined tissue or cell-type of the organ.
  • Method 20 The method of Method 19 wherein the defined cell-type is renal proximal tubule epithelial cells.
  • Method 21 The method of Method 19 or Method 20 wherein the differentially methylated regions are located at at least one of MAST4 and DDC.
  • Method 22 The method of any one of Methods 1 to 21 wherein the method further comprises treating the subject for the organ damage.
  • Method 23 A method of diagnosing kidney damage in a subject, the method comprising detecting at least one kidney differentially methylated region in cfDNA wherein the cfDNA is obtained from a biological sample of the subject, and wherein the presence of the at least one kidney differentially methylated region in the cfDNA is indicative of kidney damage.
  • Method 24 A method of detecting kidney damage in a subject, the method comprising: a) obtaining a biological sample comprising cfDNA from the subject; and b) detecting at least one kidney differentially methylated region in the cfDNA, wherein the presence of the at least one kidney-specific methylation site in the cfDNA is indicative of organ damage.
  • Method 25 The method of method 23 or method 24 wherein the method comprises detecting an increase in the level of the at least one kidney differentially methylated region relative to a reference level.
  • Method 26 The method of method of method 23 or method 24 wherein the method comprises detecting an increase in the level of the at least one kidney differentially methylated region overtime.
  • Method 27 The method of any one of methods 23 to 26 wherein the method comprises detecting cfDNA methylation status at more than one kidney differentially methylated region.
  • Method 28 The method of method 27 wherein the methylation status is determined at more than one kidney differentially methylated region using a multiplex assay.
  • Method 29 The method of any one of methods 23 to 28 wherein the methylation status is determined by a method that does not involve DNA sequencing.
  • Method 30 The method of any one of methods 23 to 29 wherein the methylation status is determined by treating the cfDNA with bisulfite and amplifying the at least one kidney differentially methylated region using polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • Method 31 The method of method 30 wherein the PCR is digital PCR (dPCR), digital droplet PCR (ddPCR) or quantitative PCR (qPCR).
  • dPCR digital PCR
  • ddPCR digital droplet PCR
  • qPCR quantitative PCR
  • Method 32 The method of any one of methods 23 to 31 wherein the subject and the organ are autologous.
  • Method 33 The method of any one of methods 23 to 32 wherein the kidney damage is associated with acute kidney injury, chronic kidney disease or kidney transplant rejection.
  • Method 34 The method of any one of methods 23 to 33 wherein the kidney damage is associated with chemotherapy or radiotherapy.
  • Method 35 The method of any one of methods 23 to 34 wherein the biological sample is urine.
  • Method 36 The method of any one of methods 23 to 35 wherein the at least one kidney differentially methylated region is located at one or more loci selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L, PAX2, chr12 - 122277360 (CLIP1), chr17 - 35303285, DEF6, EMX1 , HPD, PDE4D and SPAG5.
  • Method 37 The method of any one of methods 23 to 36 wherein the at least one kidney differentially methylated region is located at one or more loci selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L and PAX2.
  • Method 38 The method of any one of methods 23 to 37 wherein the at least one kidney differentially methylated region comprises a sequence having at least 90% identity to any one or more of SEQ ID NO. 1 , SEQ ID NO. 8, SEQ ID NO. 15, SEQ ID NO. 22 or SEQ ID NO. 29.
  • Method 39 The method of any one of methods 23 to 38 wherein the method specifically detects damage to a defined tissue or cell-type of the kidney.
  • Method 40 The method of method 39 wherein the defined cell-type is renal proximal tubule epithelial cells.
  • Method 41 The method of method 39 or method 40 wherein the at least one kidney differentially methylated regions are located at at least one of MAST4 and DDC.
  • Method 42 The method of method 39 or method 40 wherein the at least one kidney differentially methylated regions are located at at least one of GRAMD1 B and DDC.
  • Method 43 The method of method 39 or method 40 wherein the at least one kidney differentially methylated regions are located at at least one of GRAMD1 B, DDC and PAX2.
  • Method 44 The method of any one of methods 23 to 43 wherein the subject is a human.
  • Method 45 The method of any one of methods 23 to 43 wherein the subject is non-human.
  • Method 46 The method of method 45 wherein the subject is a domesticated animal.
  • Method 47 The method of method 46 wherein the domesticated animal is a companion animal.
  • Method 48 The method of method 47 wherein the domesticated animal is selected from the group consisting of sheep, cattle, horses, cats, dogs, pigs, and chickens.
  • Method 49 The method of method 47 wherein the companion animal is selected from cats and dogs.
  • Method 50 The method of any one of methods 23 to 43 wherein the method further comprises treating the subject for the kidney damage.
  • the present invention also includes the following method embodiments.
  • Method 51 A method of identifying at least one methylated region in cfDNA, said method comprising the steps of:
  • Method 52 The method of method 51 , wherein the method identifies more than one differentially methylated regions.
  • Method 53 The method of method 51 , wherein the method identifies more than one differentially methylated region using a multiplex assay.
  • Method 54 The method of any one of methods 51 to 53 wherein the identifying at least one methylated region in cfDNA is confirmed by DNA sequencing.
  • Method 55 The method of any one of methods 51 to 53 wherein the PCR is digital PCR (dPCR), digital droplet PCR (ddPCR) or quantitative PCR (qPCR).
  • Method 56 The method of any one of methods 51 to 55 wherein the at least one differentially methylated region is located at one or more loci selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L, PAX2, chr12 - 122277360, chr17 - 35303285, DEF6, EMX1 , HPD, PDE4D and SPAG5.
  • Method 57 The method of any one of methods 51 to 56 wherein the at least one differentially methylated region is located at one or more loci selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L and PAX2.
  • Method 58 The method of any one of methods 51 to 57 wherein the at least one differentially methylated region comprises a sequence having at least 90% identity to any one or more of SEQ ID NO. 1 , SEQ ID NO. 8, SEQ ID NO. 15, SEQ ID NO. 22 or SEQ ID NO. 29.
  • Method 59 The method of any one of methods 51 to 58 wherein the at least one differentially methylated region is differentially methylated in renal proximal tubule epithelial cells.
  • Method 60 The method of method 59 wherein the at least one kidney differentially methylated regions are located at at least one of MAST4 and DDC.
  • Method 61 The method of any one of methods 51 to 60 wherein the at least one kidney differentially methylated regions are located at at least one of GRAMD1 B and DDC.
  • Method 62 The method of method of any one of methods 51 to 60 wherein the at least one kidney differentially methylated regions are located at at least one of GRAMD1 B, DDC and PAX2. .
  • Method 63 The method of any one of methods 51 to 62 wherein the subject is a human.
  • Method 64 The method of any one of methods 51 to62 wherein the subject is non-human.
  • Method 65 The method of method 64 wherein the subject is a domesticated animal.
  • Method 66 The method of method 65 wherein the domesticated animal is a companion animal.
  • Method 67 The method of method 65 wherein the domesticated animal is selected from the group consisting of sheep, cattle, horses, cats, dogs, pigs, and chickens.
  • Method 68 The method of method 47 wherein the companion animal is selected from cats and dogs.
  • Method 69 The method of any one of methods 23 to 43 wherein the method further comprises treating the subject for the kidney damage.
  • Method 70 A method of indicating to a user whether or not a subject has organ damage, the method comprising: a) producing sample epigenetic data by determining a level of an organ-specific epigenetic marker in cell-free DNA (cfDNA) obtained from a biological sample of the subject; b) a processor receiving the sample epigenetic data, wherein the processor also receives reference epigenetic data corresponding to the epigenetic marker; c) the processor generating differential epigenetic data by comparing the sample epigenetic data with the reference epigenetic data; d) the processor processing the differential epigenetic data to produce a damage index value; e) determining by the processor a damage status of the subject based upon the damage index value, the damage status being indicative of whether or not the subject has organ damage; and f) transferring an indication of the organ damage of the subject to the user via a communications network.
  • cfDNA cell-free DNA
  • Method 71 The method of method 70 wherein the organ damage is kidney damage, and the organ-specific epigenetic marker is at least one kidney differentially methylated region, and the sample epigenetic data is sample methylation data and the reference epigenetic data is reference methylation data.
  • Method 72 The method of method 70 or method 71 wherein the sample methylation data is increased relative to the reference methylation data.
  • Method 73 The method of any one of methods 70 to 72 wherein the method comprises detecting an increase in the level of the sample methylation data overtime.
  • Method 74 The method of any one of methods 70 to 73 wherein the sample methylation data comprises cfDNA methylation status at more than one kidney differentially methylated region.
  • Method 75 The method of any one of method 74 wherein the methylation status is determined at more than one kidney differentially methylated region using a multiplex assay.
  • Method 76 The method of any one of methods 70 to 75 wherein the methylation data is determined by treating the cfDNA with bisulfite and amplifying the at least one kidney differentially methylated region using polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • Method 77 The method of method 76 wherein the PCR is digital PCR (dPCR), digital droplet PCR (ddPCR) or quantitative PCR (qPCR).
  • dPCR digital PCR
  • ddPCR digital droplet PCR
  • qPCR quantitative PCR
  • Method 78 The method of any one of methods 70 to 77 wherein the subject and the kidney are autologous.
  • Method 79 The method of any one of methods 70 to 78 wherein the kidney damage is associated with acute kidney injury, chronic kidney disease or kidney transplant rejection or renal replacement therapy.
  • Method 80 The method of any one of methods 70 to 79 wherein the kidney damage is associated with chemotherapy or radiotherapy.
  • Method 81 The method of any one of methods 70 to 80 wherein biological sample is urine.
  • Method 82 The method of any one of methods 71 to 81 wherein the at least one kidney differentially methylated region is located at one or more loci selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L, PAX2, chr12 - 122277360 (CLIP1), chr17 - 35303285, DEF6, EMX1 , HPD, PDE4D and SPAG5.
  • Method 82 The method of any one of methods 71 to 81 wherein the at least one kidney differentially methylated region is located at one or more loci selected from the group consisting of GRAMD1 B, DDC, MAST4, MCF2L and PAX2.
  • Method 83 The method of any one of methods 71 to 81 wherein the at least one kidney differentially methylated region comprises a sequence having at least 90% identity to any one or more of SEQ ID NO. 1 , SEQ ID NO. 2, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 22, SEQ ID NO. 23, SEQ ID NO. 29 or SEQ ID NO. 30.
  • Method 84 The method of any one of methods 71 to 83 wherein the method specifically detects damage to a defined tissue or cell-type of the kidney.
  • Method 84 The method of any one of methods 71 to 83 wherein the at least one kidney differentially methylated regions are located at at least one of MAST4 and DDC.
  • Method 85 The method of any one of methods 71 to method 83 wherein the at least one kidney differentially methylated regions are located at at least one of GRAMD1 B and DDC.
  • Method 86 The method of any one of methods 71 to method 83 wherein the at least one kidney differentially methylated regions are located at at least one of GRAMD1 B, DDC and PAX2.
  • Method 87 The method of any one of methods 71 to 86 wherein the subject is a human.
  • Method 88 The method of any one of methods 71 to 87 wherein the subject is non-human.
  • Method 89 The method of method 88 wherein the subject is a domesticated animal.
  • Method 90 The method of method 89 wherein the domesticated animal is a companion animal.
  • Method 91 The method of method 89 wherein the domesticated animal is selected from the group consisting of sheep, cattle, horses, cats, dogs, pigs, and chickens.
  • Method 92 The method of method 91 wherein the companion animal is selected from cats and dogs.
  • Method 93 At least one nucleotide primer sequence or nucleotide probe sequence when used in any one of methods 1 to 92 to detect at least one kidney differentially methylated region of cfDNA.
  • Method 94 The method of method 93 wherein the at least one nucleotide primer is two nucleotide primers when used in a PCR to detect at least one kidney differentially methylated region of cfDNA.
  • Use 1 Use of at least one kidney differentially methylated region in cfDNA in the manufacture of a reagent for diagnosing kidney damage in a subject.
  • Use 2 The use of use 1 wherein the reagent is at least one nucleotide primer or nucleotide probe, and in certain examples, two nucleotide primers configured to detect at least one kidney differentially methylated region in cfDNA.
  • DNA Methylation data from normal tissue and kidney cell types that was generated using Illumina’s Infinium Human Methylation 450K or EPIC array was sourced from publicly available data including The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) database. A total of 1 ,643 samples were downloaded, processed and collated. Cohort details are set out in Table 13 and Table 14.
  • Table 14 Other tissue sources included in bioinformatic analysis.
  • DMRs were identified for hypermethylated regions using TCGABiolinks function TCGAanalyze_DMC. Mean methylation differences were determined between bulk kidney tissue and other bulk tissue sources. A Wilcoxon test using the Benjamini-Hochberg adjustment method was used to estimate p-values. A differential methylation difference of > 0.25 with a false discovery rate (FDR)- adjusted Wilcoxon rank-sum P-value of ⁇ 10’ 05 was used to identify hypermethylated probes. The threshold for differential methylation was chosen to enable detection of DMRs that were driven by high methylation levels within specific cell types.
  • FDR false discovery rate
  • methylation levels were plotted across the region within 5,000 base pairs ( Figure 1). Different kidney cell types were included in these plots including Human Renal Proximal Tubule Epithelial Cells (RPTEC), Human Cultured Podocytes and Human Renal Cortical Epithelial cells. These plots were individually reviewed, and a shortlist was created (Table 15) based on separation between tissue types and large methylation differences between RPTEC and other tissues.
  • RPTEC Human Renal Proximal Tubule Epithelial Cells
  • Table 15 Human Renal Cortical Epithelial cells
  • Table 15 Shortlisted regions from bioinformatic assessment.
  • cfDNA was extracted from biological samples (plasma, urine, tissue etc) using a QIAamp circulating nucleic acid kit (Qiagen, Cat# 55114) as per the manufacturer’s instructions.
  • the eluted DNA was then bisulfite converted using EZ DNA Methylation-Lightning kit (Zymo, Cat# D5030), or EpiTect Fast DNA Bisulfite kit (Qiagen, Cat# 59824), as per the manufacturer’s instructions.
  • the resulting bisulfite converted DNA was analysed using qPCR or dPCR assays designed to amplify the target strands of one or more of the following targets: PAX2 (SEQ ID NOs 5-7), GRAMD1B (SEQ ID NOs 12-14), DDC (SEQ ID NOs 19-21), MAST4 (SEQ ID NOs 26-28) or MCF2L (SEQ ID NOs 33-35).
  • ACTB amplification was also used as a control to ensure that the extraction (SEQ ID NOs 38-40 for detection of native ACTB sequence), or bisulfite conversion and PCR worked (SEQ ID NOs 43-45 for detection of bisulfite converted ACTB sequence).
  • qPCR reactions comprised 7.5 p.L GoTaq Hot Start Colourless mastermix, 2 mM MgCl2, 200 nM of each Forward and Reverse primers, 100 nM fluorescently labelled hydrolysis probe, and template DNA made up to 15 p.L final volume, and were cycled as follows: 95°C, 2 mins; [95°C, 15 secs; 62°C, 30 secs, 72°C, 30 secs with acquisition] x 50; 40 °C, 10 secs, on a QuantStudio7 real-time PCR system (ThermoFisher).
  • reactions comprised 10 p.L QIAcuity probe PCR mix (Qiagen, Cat# 250103), 800 nM of each Forward and Reverse primers, 400 nM fluorescently labelled hydrolysis probe, and template DNA made up to 40 p.L final volume, and were cycled as follows: 95°C, 2 mins; [95°C, 15 secs; 61°C, 30 secs with acquisition] x 40 on the QIAcuity 4 plate digital PCR system (Qiagen).
  • the sequence of the top strand (SEQ ID NO. 8) and the bottom strand (SEQ ID NO. 9) of the PCR assay region are shown in Figure 3A.
  • the sequence of the top strand (SEQ ID NO. 15) and the bottom strand (SEQ ID NO. 16) of the PCR assay region are shown in Figure 4A.
  • the sequence of the top strand (SEQ ID NO. 22) and the bottom strand (SEQ ID NO. 23) of the PCR assay region are shown in Figure 5A.
  • the amplicon is situated in the +2 kb upstream promoter region.
  • the sequence of the top strand (SEQ ID NO. 36) and the bottom strand (SEQ ID NO. 37) of the PCR assay region are shown in Figure 7A.
  • the forward and reverse primers, and the oligonucleotide probe used to detect the ACTB sequence are listed in Table 21 .
  • Loci that are differentially methylated in kidney cells/tissues relative to blood and other tissues were identified bioinformatically and specific primers and probes were designed to these regions as described above. A number of different assays were designed to each of five DMRs, and these were tested analytically to identify the best performing assays for each DMR (SEQ ID NOs 1-35).
  • DNA from 14 different tissue types comprising adipose, adrenal, brain, breast, colon, heart, kidney, liver, lung, pancreas, skeletal, skin and spleen, alongside commercially sourced fully unmethylated DNA (CpGenome universal unmethylated DNA, Sigma, Cat# S7822) and Human genomic DNA from buffy coat (PBMC, Sigma, Cat# 11691112001) were bisulfite converted using EZ DNA Methylation-Lightning kit (Zymo, Cat# D5030), or EpiTect Fast DNA Bisulfite kit (Qiagen, Cat# 59824), as per the manufacturer’s instructions.
  • a standard curve for each assay was prepared by amplifying 2.5-fold serial dilutions of bisulfite converted fully methylated DNA (Zymo, Cat# D5011) from 5000 pg/reaction to 8.2 pg/reaction, or 500 copies/reaction to 0.82 copies/reaction, in quadruplicate and this was used to calculate the amount of DNA amplified for each gene.
  • qPCR reactions comprised 7.5 p.L GoTaq Hot Start Colourless mastermix, 2 mM MgCl2, 200 nM of each Forward and Reverse primers, 100 nM fluorescently labelled hydrolysis probe, and template DNA made up to 15 p.L final volume, and were cycled as follows: 95°C, 2 mins; [95°C, 15 secs; 62°C, 30 secs, 72°C, 30 secs with acquisition] x 50; 40 °C, 10 secs, on a QuantStudio7 real-time PCR system (ThermoFisher).
  • Figure 8 shows the results of a representative assay designed against each of the five DMR genes assayed. It can be seen that each assay strongly detects kidney DNA as well as some low-level positivity in some other tissues. Typically, this off-target amplification is ⁇ 1 % of the target amplification, with an occasional sample being higher than this, but when applied to a cfDNA scenario, where typical yields are ⁇ 10 ng/mL plasma or 5 ng/mL urine for total cfDNA, and only a fraction of this is derived from these organs/tissues, except liver, then this low-level positivity is generally inconsequential.
  • the five selected assays were then tested in plasma obtained from presumed healthy individuals under 30 years of age to determine if there was any background signal.
  • cfDNA from two aliquots of 3 mL plasma was extracted using a QIAamp circulating nucleic acid kit (Qiagen, Cat# 55114) as per the manufacturer’s instructions.
  • the eluted DNA from the two aliquots for each sample was combined and then bisulfite converted using EZ DNA Methylation-Lightning kit (Zymo, Cat# D5030), or EpiTect Fast DNA Bisulfite kit (Qiagen, Cat# 59824), as per the manufacturer’s instructions.
  • a standard curve for each assay was prepared by amplifying 2.5-fold serial dilutions of bisulfite converted fully methylated DNA (Zymo, Cat# D5011) from 5000 pg/reaction to 8.2 pg/reaction, or 500 copies/reaction to 0.82 copies/reaction, in quadruplicate and this was used to calculate the amount of DNA amplified for each gene.
  • qPCR reactions comprised 7.5 p.L GoTaq Hot Start Colourless mastermix, 2 mM MgCL, 200 nM of each Forward and Reverse primers, 100 nM fluorescently labelled hydrolysis probe, and template DNA made up to 15 p.L final volume, and were cycled as follows: 95°C, 2 mins; [95°C, 15 secs; 62°C, 30 secs, 72°C, 30 secs with acquisition] x 50; 40 °C, 10 secs, on a QuantStudio7 real-time PCR system (ThermoFisher).
  • Figure 9 shows that very little signal is obtained for any of the kidney-specific assays in plasma and where a signal was detected, the % of the total kidney cfDNA was typically ⁇ 0.1%. Only GRAMD1 B gave a higher signal than this (1.26% of total kidney cfDNA) in one sample only. As these samples are from presumed healthy donors, rather than from individuals who are confirmed to be free of kidney disease, it is possible that donor HMN569764 had an underlying kidney condition that gave rise to the low-level positivity seen in 3 of the 5 markers tested.
  • the five selected assays were then tested in urine obtained from 20 presumed healthy individuals aged 26-61 to determine if there was any background signal.
  • the cfDNA from two aliquots of 3 mL urine was extracted using a QIAamp circulating nucleic acid kit (Qiagen, Cat# 55114) as per the manufacturer’s instructions.
  • the eluted DNA from the two aliquots for each sample was combined and then bisulfite converted using EZ DNA Methylation-Lightning kit (Zymo, Cat# D5030), or EpiTect Fast DNA Bisulfite kit (Qiagen, Cat# 59824), as per the manufacturer’s instructions.
  • dPCR reactions comprised 10 p.L QIAcuity probe PCR mix (Qiagen, Cat# 250103), 800 nM of each Forward and Reverse primers, 400 nM fluorescently labelled hydrolysis probe, and template DNA made up to 40 p.L final volume, and were cycled as follows: 95°C, 2 mins; [95°C, 15 secs; 61°C, 30 secs with acquisition] x 40 on the QIAcuity 4 plate digital PCR system (Qiagen).
  • Figure 10 shows that the situation is quite different in urine, compared to plasma. All of the differentially methylated loci amplify strongly and contribute a significant amount of signal (mostly ⁇ 1- 20%) compared to total kidney cfDNA. As these samples were obtained from patients with a range of ages, we looked to see if there was a correlation with age and increasing signal, and it was noticed that this was indeed the case, especially when considering the signal as a percentage of total cfDNA. An increase in amount or proportion of kidney-specific cfDNA may be indicative of acute kidney injury or chronic kidney disease and could indicate a decline in kidney function with age.
  • the eluted DNA was quantified in dPCR using the ACTB assay (SEQ ID NOs 43-45) and subsequently diluted in 1 ng/mL cRNA as a stabiliser so that each PCR well contained 0.17 copies of amplifiable DNA.
  • a 384-well qPCR plate was set up for each kidney-specific assay containing either 320 or 343 wells of low concentration bisulfite converted methylated DNA and a standard curve for each assay was prepared by amplifying 2.5-fold serial dilutions of bisulfite converted fully methylated DNA (Zymo, Cat# D5011) from 5000 pg/reaction to 8.2 pg/reaction, or 500 copies/reaction to 0.82 copies/reaction, in quadruplicate.
  • qPCR reactions for each assay targeting PAX2 (SEQ ID NOs 5-7), GRAMD1B (SEQ ID NOs 12-14), DDC (SEQ ID NOs 19-21), MAST4 (SEQ ID NOs 26-28), or MCF2L (SEQ ID NOs 33- 35) comprised 7.5 p.L GoTaq Hot Start Colourless mastermix, 2 mM MgCl2, 200nM of each Forward and Reverse primers, 100 nM fluorescently labelled hydrolysis probe, and template DNA made up to 15 p.L final volume, and were cycled as follows: 95°C, 2 mins; [95°C, 15 secs; 62°C, 30 secs, 72°C, 30 secs with acquisition] x 50; 40 °C, 10 secs, on a QuantStudio7 real-time PCR system (ThermoFisher). Three consecutive wells were combined to emulate a sample tested in triplicate. Therefore, individual replicate positivity is expected at 17% and sample positivity at ⁇ 50
  • Table 23 Summary of individual replicate positivity, sample positivity (3 replicates combined) and 95% confidence intervals for % positivity of the proportion for a variety of kidney-specific assays directed against the differentially methylated regions of GRAMD1B, DDC, MAST4, MCF2L and PAX2 genes. Each well contained 0.17 copies of DNA, as measured by dPCR.
  • kidney-specific cfDNA Detection of kidney-specific cfDNA in kidney transplant patients
  • DNA was extracted from 57 clinical specimens taken from 25 kidney transplant patients at various time points pre- and post-renal transplant. Where available, the DNA from the equivalent of 1 mL plasma for each time point was extracted using a QIAamp circulating nucleic acid kit (Qiagen, Cat# 55114) as per the manufacturer’s instructions. The eluted DNA was then bisulfite converted using EZ DNA Methylation-Lightning kit (Zymo, Cat# D5030), or EpiTect Fast DNA Bisulfite kit (Qiagen, Cat# 59824), as per the manufacturer’s instructions.
  • Qiagen Qiagen, Cat# 55114
  • the eluted DNA was then bisulfite converted using EZ DNA Methylation-Lightning kit (Zymo, Cat# D5030), or EpiTect Fast DNA Bisulfite kit (Qiagen, Cat# 59824), as per the manufacturer’s instructions.
  • the resulting bisulfite converted DNA was analysed using qPCR or dPCR assays designed to amplify the target strands of the following targets: PAX2 (SEQ ID NOs 5-7), GRAMD1B (SEQ ID NOs 12-14), and DDC (SEQ ID NOs 19-21).
  • ACTB amplification was also used as a control to ensure that the extraction, bisulfite conversion and PCR worked (SEQ ID NOs 43-45).
  • qPCR reactions comprised 7.5 p.L GoTaq Hot Start Colourless mastermix, 2 mM MgCl2, 200 nM of each Forward and Reverse primers, 100 nM fluorescently labelled hydrolysis probe, and template DNA made up to 15 p.L final volume, and were cycled as follows: 95°C, 2 mins; [95°C, 15 secs; 62°C, 30 secs, 72°C, 30 secs with acquisition] x 50; 40 °C, 10 secs, on a QuantStudio7 real-time PCR system (ThermoFisher).
  • reactions comprised 10 p.L QIAcuity probe PCR mix (Qiagen, Cat# 250103), 800 nM of each Forward and Reverse primers, 400 nM fluorescently labelled hydrolysis probe, and template DNA made up to 40 p.L final volume, and were cycled as follows: 95°C, 2 mins; [95°C, 15 secs; 61 °C, 30 secs with acquisition] x 40 on the QIAcuity 4 plate digital PCR system (Qiagen).
  • PAX2 has mean concentration of 0.34 c/mL pre-transplant, and 12.08 c/mL at 24h and Oc/mL at 168h; GRAMD1 B has mean concentration of 0.51 c/mL pre-transplant, 8.47 c/mL at 24h and Oc/mL at 168h; and DDC has mean concentration of 0.88 c/mL pre-transplant, and 3.67 c/mL at 24h and 6.51 c/mL at 168h.
  • kidney-specific cfDNA detectable pretransplant these patients are generally in renal failure and have no functional kidney remaining prior to transplant. The levels of cfDNA detected are typically highest within 24 hours post-transplant and start to return to baseline levels by day 7. These results are consistent with results using donor-derived cfDNA to monitor transplant.
  • PAX2 provides the highest level of signal, with 1-1 .2% of the total cfDNA within the 24 hours post-transplant.
  • Cell specific Biomarkers Cell-specific data is less abundant in the public domain. To identify differentially methylated regions in cells within the kidney, a 0.25 methylation difference cut off was used to identify low-level differentially methylation regions in bulk kidney tissue and then be further evaluated in cell-specific data to determine the methylation proportion in these specific cell types. Data was sourced for Renal Proximal Tubule Epithelial Cells (31 samples from human subjects GSE115227, GSE145745, and GSE126441), human cultured podocytes (2 samples from human subject GSE41689), and human Renal Cortical Epithelial cells (1 sample from human subject GSE126441). These cell types were selected to evaluate the methylation status of the identified probes that exhibited low levels of methylation as shown in Figure 12.
  • PAX2 (cg23206032) was found to be highly methylated in all cell types and was the only region developed for PCR that was positive in the renal cortical epithelial cells. Both DDC and MAST4 were specific for the renal proximal tubule epithelial cells (RPTEC). This could be advantageous for early detection of injury and prognosis given the crucial role of RPTEC’s in kidney function, including reabsorption of water, electrolytes, and nutrients. MCF2L and GRAMD1B had a similar profile to DDC and MAST4 but did show methylation in podocytes.
  • ND indicates not done, and a blank well indicates no amplification in any replicates.
  • profiles observed were similar to array data with exceptional specificity for DNA extracted from bulk kidney tissue.
  • a triplex assay was prepared for PAX2, DDC and GRAMD1B.
  • the preferred PCR designs to detect human kidney differentially methylated regions have been included in Figures 23-27 and Tables 12, 16-20.
  • Kidney specific methylation biomarker comparison in urine samples from subjects with various stages of CKD Kidney specific methylation biomarker comparison in urine samples from subjects with various stages of CKD.
  • RPTECs Renal Proximal Tubule Epithelial Cells
  • Urine samples were collected from presumed healthy adult cohort with no known kidney disease and patients pre- and post- heart transplant surgery. Post-transplant samples were split into two groups, those with severe AKI within 48 hours post-surgery and those with no or moderate AKI post-surgery. Categorisation was determined based on RIFLE criteria for fold change in creatine from baseline.
  • ACTB is a measurement total cfDNA and shows increased levels in heart transplant patients with severe AKI post-surgery (see Figure 16).
  • kidney cfDNA release as a result of injury increased total cfDNA in urine.
  • the level of total cfDNA measurement lacks specificity and does not discriminate between cfDNA increases due to other biological variability including exercise, inflammation, and infection.
  • FIG. 18 A-D show total cfDNA (A) and kidney specific cfDNA (B-D) in both urine (left y-axis) and plasma (right-axis).
  • Figure E provides the standard of care markers for the patient, including creatinine (pmol/mL), eGFR (ml/min/1.73 m 2 ) and urine output (mL) using a rolling 6-hour average based on hourly readings. The time of x-axis for all plots is time from surgery. As shown in Figure E, the patient had a steep rise in creatinine with a greater than 3-fold increase in creatinine over baseline post-surgery, concomittant with a decrease in urine output.
  • the bulk kidney cfDNA marker, PAX2 is elevated in urine immediately post-surgery (5,928 cps/mL of urine) over baseline (226 cps/mL of urine) 10 hours prior to creatinine increasing to 2.14 over baseline and 33 hours prior to exceeding a 3-fold increase.
  • the corresponding matched blood sample for PAX2 is low for the first sample but highly elevated for the second sample, where urine PAX2 cfDNA is decreasing. This indicates that urine is the primary sample for early detection and release of kidney cfDNA in plasma is delayed. It also indicates that although total cfDNA increases dramatically in plasma post-surgery, this does not contain kidney cfDNA and thus total cfDNA is a poor marker for assessment of kidney damage.
  • tubular specific (DDC) and tubular/podocyte specific (GRAMD1B) markers in cfDNA are low until the second sample ( ⁇ 24 hours post surgery) and may indicate the delay in release of tubular DNA post injury and represent acute tubular necrosis. From this sample the tubular specific cfDNA concentration remains elevated and erratic and can be a predictor of long-term kidney damage. The levels seen in Patient 1 have only been repeated in patients receiving dialysis in ICU.
  • kidney damage occurring within the RPTECs is clinically significant for several reasons. RPTECs play a crucial role in kidney function, including reabsorption of essential substances and maintenance of electrolyte balance. Damage to RPTECs can disrupt these critical functions, leading to impaired kidney function and potentially contributing to the development or progression of kidney diseases.
  • RPTEC damage By determining if the observed damage is specifically occurring within the RPTECs, clinicians can gain insights into the underlying mechanisms and pathophysiology of the kidney injury. This knowledge can help guide treatment strategies and interventions targeted towards preserving RPTEC function and promoting renal recovery. Identifying RPTEC damage also provides important diagnostic and prognostic information. It can serve as an indicator of the severity and extent of kidney injury and help predict the likelihood of adverse outcomes or complications. This information is crucial for patient management, including determining appropriate therapies, monitoring disease progression, and assessing the effectiveness of interventions aimed at preserving renal function.
  • Oligonucleotides were designed to feline PAX2 in two different regions with substantial sequence identity to that of the human PAX2 marker. These oligonucleotides are shown in Table 12 as SEQ ID 50, SEQ ID 51 and SEQ ID 52 (assay PAX2-A), and SEQ ID 57, SEQ ID 58 and SEQ ID 59 (assay PAX2-B).
  • dPCR reactions comprised 10 p.L QIAcuity probe PCR mix (Qiagen, Cat# 250103), 800 nM of each Forward and Reverse primers, 400 nM fluorescently labelled hydrolysis probe, and template DNA made up to 40 p.L final volume, and were cycled as follows: 95°C, 2 mins; [95°C, 15 secs; 60°C, 30 secs with acquisition] x 40 on the QIAcuity 4 plate digital PCR system (Qiagen).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Les modifications épigénétiques jouent un rôle important dans la régulation des profils d'expression spécifiques des cellules. Par exemple, différentes signatures de méthylation de l'ADN peuvent être trouvées dans différents tissus et même dans différents types de cellules d'un tissu particulier. Selon la présente invention, les inventeurs ont découvert que ces signatures de méthylation peuvent être utilisées pour identifier un tissu d'origine d'un ADN libre circulant (ADNlc). De plus, ces nouveaux marqueurs de méthylation peuvent être utilisés pour détecter des lésions cellulaires, tissulaires ou organiques, y compris des lésions cellulaires, tissulaires ou organiques autologues.
PCT/AU2023/050562 2022-06-21 2023-06-21 Détection de lésions cellulaires WO2023245245A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2022901697 2022-06-21
AU2022901697A AU2022901697A0 (en) 2022-06-21 Detection of cell damage

Publications (1)

Publication Number Publication Date
WO2023245245A1 true WO2023245245A1 (fr) 2023-12-28

Family

ID=89378732

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2023/050562 WO2023245245A1 (fr) 2022-06-21 2023-06-21 Détection de lésions cellulaires

Country Status (1)

Country Link
WO (1) WO2023245245A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018099418A1 (fr) * 2016-11-30 2018-06-07 The Chinese University Of Hong Kong Analyse d'adn acellulaire dans l'urine et d'autres échantillons
US20200048713A1 (en) * 2017-04-06 2020-02-13 Cornell University Methods of detecting cell-free dna in biological samples

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018099418A1 (fr) * 2016-11-30 2018-06-07 The Chinese University Of Hong Kong Analyse d'adn acellulaire dans l'urine et d'autres échantillons
US20200048713A1 (en) * 2017-04-06 2020-02-13 Cornell University Methods of detecting cell-free dna in biological samples

Similar Documents

Publication Publication Date Title
CN105765083B (zh) 基于表观遗传学标记物来估计组织和细胞类型的年龄的方法
JP2020174678A (ja) 非侵襲的出生前診断に有用な母体試料由来の胎児核酸のメチル化に基づく富化のためのプロセスおよび組成物
JP5902843B2 (ja) Ｉｇｆ２遺伝子の対立遺伝子特異的な発現を判定するための一塩基多型ならびに新規および公知の多型の組み合わせ
US10697014B2 (en) Genomic regions with epigenetic variation that contribute to phenotypic differences in livestock
WO2007011412A9 (fr) Diagnostic et pronostic de phenotypes cliniques de maladies infectieuses et d'autres etats biologiques au moyen de marqueurs de l'expression genique hotes dans le sang
US10889862B2 (en) Methods for identifying and using small RNA predictors
US20220298581A1 (en) COMPOSITIONS AND METHODS OF USING HisGTG TRANSFER RNAS (tRNAs)
US20220073986A1 (en) Method of characterizing a neurodegenerative pathology
KR101992792B1 (ko) Akr1e2 유전자의 메틸화 수준을 이용한 비만의 예측 또는 진단을 위한 정보제공방법 및 이를 위한 조성물
CN115572765B (zh) 一组肿瘤检测标志物及其用途
CN114574584B (zh) 一组肿瘤检测标志物及其用途
CN115572764B (zh) 一组肿瘤检测标志物及其用途
CN103789408A (zh) 高血压易感基因组的鉴定
CN106834501B (zh) 与中国儿童肥胖相关的单核苷酸多态性位点及其应用
WO2020254405A1 (fr) Prédiction de l'âge à l'aide de signatures de méthylation de l'adn
CN111788317B (zh) 用于表征癌症的组合物和方法
US9822412B2 (en) Detection of DNA that originates from a specific cell-type
KR102409747B1 (ko) Snx20 유전자의 메틸화 수준을 이용한 비만의 예측 또는 진단을 위한 조성물 및 이를 위한 정보 제공방법
CN106811545B (zh) 一种预测高甘油三酯血症的易感性的方法与试剂
WO2023245245A1 (fr) Détection de lésions cellulaires
US20240084389A1 (en) Use of simultaneous marker detection for assessing difuse glioma and responsiveness to treatment
WO2020254364A1 (fr) Prédiction de lésion d'allogreffe chronique par méthylation d'adn liée à l'âge
US20190316199A1 (en) Test method for evaluating the risk of anti-thyroid drug-induced agranulocytosis, and evaluation kit
KR101777911B1 (ko) 골다공증 골절 발생 예측용 바이오마커
US20170240965A1 (en) Methods for prognosing heart transplant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23825693

Country of ref document: EP

Kind code of ref document: A1